CAR T-Cell Therapy | Clinical

Using CAR T-Cell Therapy Earlier May Produce More Benefit in ALL

July 08, 2021

Bijal Shah, MD, MS, discusses the timing of treatment with chimeric antigen receptor T-cell therapy in regard to the data from the ZUMA-3 trial of brexucabtagne autoleucel in patients with acute lymphoblastic leukemia.

Cilta-Cel Shows High Response Rate Even After Longer Follow-Up in R/R Multiple Myeloma

June 16, 2021

Updated results from the phase 1/2 CARTITUDE-1 trial showed that responses to ciltacabtagene autoleucel were deep and durable in patients with relapsed or refractory multiple myeloma. Data at a median follow-up of 18 months were presented at the 2021 European Hematology Association Congress.

CAR T Therapy Effective for Numerous Hematologic Malignancies, Even in Heavily Pretreat Patients

May 27, 2021

In an interview with Targeted Oncology, Deepu Madduri, MD discussed the need for further CAR T-cell therapy research, expanding it into other hematology malignancies. She also discussd management of the common adverse events associated with CAR T cells.